Brexit
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
'Get Your Skates On', UK Firms Planning M&A Warned
UK pharma groups planning M&A deals ‘must get their skates on’ and begin filing now if they want to benefit from the EU’s review process before the Brexit transition period ends on 31 December.
Brexit Finally Here But Uncertainty Not Over For Biopharma
A free trade deal needs to be negotiated in record time and UK life sciences must face up to diverging from the EU.
Latest From Brexit
UK's Post-Brexit Medicine Plans Under Pressure
UK proposals for limited cooperation with the EU in medicines regulation, including the recognition of certificates and inspections, are one glimmer of light in an otherwise uncertain post-Brexit regulatory scenario for the UK. But time pressures and political spats over the future relationship could throw the whole enterprise into doubt.
UK Devices Bill Back On The Agenda As Govt Tries To Get COVID-19 Crisis Under Control
Post-Brexit planning is now fully back on the agenda in the UK, and work to shape its post-EU medtech regulatory future is also restarting.
UK Row Over COVID-19 EU Procurement Scheme Erupts Again As UK Promises Future Involvement
The UK’s ventilator and personal protective equipment shortage has been well-documented, and questions over its failure to be part of an EU procurement scheme refuse to go away.
EU Regulatory Round-Up: RWE Platform Proposed, Brexit Transition Update, EPI Principles Published
The latest EU regulatory developments - EMA and HMA are looking to build an EU-wide real-world data platform; EU OTC firms can operate as normal in the UK until the end of the year; EMA, HMA and the EC have published key principles on how to develop and use electronic product information for medicines marketed within the EU.
UK’s Brexit Talks Another Victim Of Coronavirus – FTA Plans With EU Could Be In Jeopardy
The second round of the UK’s talks on exiting the EU by the end of the year have been called off over COVID-19, but whether this is a temporary derailment or a more structural issue for the UK’s planned EU separation is the question emerging.
A Global Approach To Medtech Regulation: The Post-EU Way Ahead For UK Industry?
As the UK looks to its future healthtech regulatory model after Brexit, the ABHI’s regulatory director Phil Brown suggests a system whereby the same product data can be used as the basis for entry not only to the EU, but also to global markets.
UK Devices Bill Offers Medtech An EU MDR Alternative – Or Better?
With the obvious distractions of coronavirus, the UK Medicines and Medical Devices bill has entered its second reading in parliament, accompanied by a drive for it to succeed from the government and opposition parties.
UK To Seek Only Limited Regulatory Alignment With EU
Despite the life sciences industry’s call for continued alignment of medicines regulation with the EU from next year and for some sort of co-operation with the European Medicines Agency, it seems the UK government is prepared to make only small concessions.
‘No Unified Patent Court For Us’, Says UK Government
The UK’s decision to pull out of Europe’s Unified Patent Court system throws the future of the whole project into doubt.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Article
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.